XRHealth and HTC Introduce “Flow Health” and “Focus 3 Health” at HIMSS 2022

Both Solutions Provide Portable Virtual Reality Healthcare Solutions for Hospitals, Rehabilitation Centers, and Patients to Use in the Comfort of their Home

XRHealth, the gateway to the healthcare metaverse,  and HTC VIVE, the global leader in premium virtual reality (VR),  announced today “Focus 3 Health” and “Flow Health” powered by XRHealth.

The two separate products using HTC VIVE Focus 3 and HTC VIVE Flow are preloaded with the XRHealth virtual reality treatment rooms and other VR health applications, so that hospitals, rehabilitation centers and individual patients can benefit from remote VR telehealth, no matter where they are.

Individual patients can purchase “Flow Health” for $599. The bundle includes the VIVE Flow immersive glasses, preloaded with XRHealth FDA registered medical applications, and includes a screening video call with an XRHealth clinician. Patients can then sign up for VR Telehealth treatment with an XRHealth clinician, covered by their health plan or pay out of pocket for $69-$119 per week, according to the tier they choose.

Hospitals and rehabilitation centers can purchase the “Focus 3 Health” solution for a $1300 one-time fee, which includes the VIVE Focus 3 headset and the preinstalled XRHealth medical platform. The XRHealth medical platform applications are a subscription service of $1000/month. The devices will be sold under the guidelines and regulations of durable medical equipment and will be FSA/HSA eligible.

“XRHealth, together with HTC, are excited to offer the public VR products specifically designed for the healthcare market,” says Eran Orr, Chief Executive Officer of XRHealth. “We believe in creating healthcare solutions that are limitless and provide continuous access and healthcare opportunities to patients around the globe.”

XRHealth’s healthcare VR applications are FDA and CE registered and transport patients to a virtual clinic, where symptoms of stress, anxiety, depression, ADHD, autism, multiple sclerosis, Parkinson’s Disease, and physical and neurological injuries are treated.  When the patient is in the treatment room, comprehensive data can be measured providing the clinician with valuable insights on treatment progress and outcome.

“At HTC, we believe in the power of VR to change lives,” said Amir Khorram, VP of Enterprise Sales, at HTC VIVE. “We are honored to partner with XRHealth on Flow Health and Focus 3 Health – two innovative solutions centered around the power of the VIVE Focus 3 and the lightweight portability of the VIVE Flow, to offer patients and clinicians immersive remote VR telehealth treatments.”

Both products will be available in June. Customers can preorder here, beginning May 1, 2022.

SourceXRHealth

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.